These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26988824)

  • 21. [Impact of response of positive axillary nodes to neoadjuvant chemotherapy on breast cancer survival].
    Wang X; He YJ; Ying M; Li JF; Xie YT; Wang TF; Fan ZQ; Fan T; Ouyang T
    Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2116-9. PubMed ID: 22093987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
    Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
    Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy.
    Kim H; Park W; Huh SJ; Choi DH; Noh JM; Im YH; Ahn JS; Park YH; Nam SJ; Kim SW; Lee JE; Cho EY
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):329-336. PubMed ID: 27869361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype].
    Cirier J; Body G; Jourdan ML; Bedouet L; Fleurier C; Pilloy J; Arbion F; Ouldamer L
    Gynecol Obstet Fertil Senol; 2017 Oct; 45(10):535-544. PubMed ID: 28939364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
    Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
    Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
    Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of stages of axillary lymph nodes and pathological response to neoadjuvant chemotherapy on the survival of breast cancer patients].
    Wang W; Zhang B; Xu X; Wang X; Zhang P; Wang X
    Zhonghua Zhong Liu Za Zhi; 2015 Mar; 37(3):195-9. PubMed ID: 25975788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
    Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
    Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
    Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Kim SI; Sohn J; Koo JS; Park SH; Park HS; Park BW
    Oncology; 2010; 79(5-6):324-30. PubMed ID: 21430399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer].
    Liu WQ; Ye JM; Xu L; Liu Q; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):706-9. PubMed ID: 24252676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
    Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
    Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.